Idelalisib in the management of lymphoma-Reference-Cited by-同舟云学术

Idelalisib in the management of lymphoma

Published:2016-07-21 Issue:3 Volume:128 Page:331-336
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Cheah Chan Yoon¹²,Fowler Nathan H.³

Affiliation:

1. Department of Haematology, Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Nedlands, WA, Australia;

2. University of Western Australia, Crawley, WA, Australia; and

3. The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract

Abstract Inhibition of the phosphatidylinositol-3-kinase (PI3K) pathway as an anticancer therapeutic strategy was realized with the approval of the orally bioavailable small molecule PI3Kδ inhibitor idelalisib. In this focused review, we highlight the rationale for targeting the pathway in lymphomas, provide a brief summary of the preclinical data, and describe the clinical experience with this agent in patients with lymphoma. We describe some of the idiosyncratic toxicities of this agent, some of the mechanisms of resistance, and some of the ongoing combination strategies.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/3/331/1359041/331.pdf

Reference52 articles.

1. The PI3K pathway as drug target in human cancer.;Courtney;J Clin Oncol,2010

2. Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib.;Maffei;J Hematol Oncol,2015

3. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.;Shah;Ann Pharmacother,2015

4. Targeted therapies in CLL: mechanisms of resistance and strategies for management.;Woyach;Blood,2015

5. PI3K signalling: the path to discovery and understanding.;Vanhaesebroeck;Nat Rev Mol Cell Biol,2012

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of novel 2-substituted 2, 3-dihydroquinazolin-4(1H)-one derivatives as tubulin polymerization inhibitors for anticancer therapy: The in vitro and in vivo biological evaluation;European Journal of Medicinal Chemistry;2024-11

2. Targeted small molecule therapy and inhibitors for lymphoma;Future Medicinal Chemistry;2024-07-17

3. PI3K Inhibitors in Hematology: When One Door Closes…;Clinical Cancer Research;2024-07-05

4. Clinical Mycology Today: Emerging Challenges and Opportunities;Open Forum Infectious Diseases;2024-06-27

5. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas;Life Sciences;2024-06